World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 12 May 2014
Main ID:  EUCTR2009-016488-12-IT
Date of registration: 18/05/2011
Prospective Registration: Yes
Primary sponsor: MILLENNIUM PHARMACEUTICALS, INC.
Public title: A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn’s Disease - ND
Scientific title: A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn’s Disease - ND
Date of first enrolment: 23/03/2011
Target sample size: 396
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-016488-12
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no  
Phase: 
Countries of recruitment
Austria Belgium Czech Republic Germany Hungary Italy Netherlands
Contacts
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria:
1. Age 18 to 80. 2. Male or female patient who is voluntarily able to give informed consent.Female patients who: ? Are postmenopausal for at least 1 year before screening, OR ? Are surgically sterile, OR ? If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form (ICF) through 6 months after the last dose of study drug, OR agree to completely abstain from heterosexual intercourse. Male patients, even if surgically sterilized (ie, status postvasectomy), who: ? Agree to practice effective barrier contraception during the entire study treatment period and through 6 months after the last dose of study drug, OR ? Agree to completely abstain from heterosexual intercourse. 4. Diagnosis of CD established at least 3 months before enrollment by clinical and endoscopic evidence and corroborated by a histopathology report. Cases of CD established at least 6 months before enrollment for which a histopathology report is not available will be considered based on the weight of the evidence supporting the diagnosis and excluding other potential diagnoses, and must be discussed with the sponsor’s (or designee’s) medical monitor on a case-by-case basis before enrollment. 5. Moderately to severely active CD as determined by a CDAI score of 220 to 400(see Section 15.1) within 7 days before enrollment and 1 of the following: a. CRP level > 2.87 mg/L during the Screening period, OR b. Ileocolonoscopy with photographic documentation of a minimum of 3 nonanastomotic ulcerations (each > 0.5 cm in diameter) or 10 aphthous ulcerations (involving a minimum of 10 contiguous cm of intestine) consistent with CD, within 4 months before enrollment, ORFecal calprotectin = 250 ?g/g stool during the Screening period in conjunction with computed tomography (CT) enterography, magnetic resonance (MR) enterography, contrast-enhanced small bowel radiography, or wireless capsule endoscopy revealing Crohn’s ulcerations (aphthae not sufficient), within 4 months before screening. (Patients with evidence of fixed stenosis or small bowel stenosis with prestenotic dilation should not be included.) 6. CD involvement of the ileum and/or colon, at a minimum. 7. Patients with extensive colitis or pancolitis of > 8 years duration or limited colitis of > 12 years duration must have documented evidence that a surveillance colonoscopy was performed within 12 months before enrollment (may be performed during screening). 8. Patients with a family history of colorectal cancer, personal history of increased colorectal cancer risk, age > 50 years, or other known risk factor must be up-todate on colorectal cancer surveillance (may be performed during screening).Demonstrated, over the previous 5-year period, an inadequate response to, loss of response to, or intolerance of at least 1of the following agents as defined below: ? Immunomodulators o Signs and symptoms of persistently active disease despite a history of at least one 8-week regimen of oral azathioprine (= 1.5 mg/kg) or 6-MP (= 0.75 mg/kg), OR o Signs and symptoms of persistently active disease despite a history of at least one 8-week regimen of methotrexate (= 12.5 mg/week), OR o History of intolerance of at least 1 immunomodulator (including, but not limited to, nausea/vomiting, abdominal pain, pancreatitis, liver function test abnormalities, lymphopenia, TPMT genetic mutation, infecti

Exclusion criteria:
1. Evidence of abdominal abscess during screening 2. Extensive colonic resection or subtotal or total colectomy 3. History of > 3 small bowel resections or diagnosis of short bowel syndrome4. Have received tube feeding, defined formula diets, or parenteral alimentation within 21 days before enrollment 5. Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine 6. Within 30 days before enrollment, have received any of the following for the treatment of underlying disease: a. Nonbiologic therapies (eg, cyclosporine, thalidomide) other than those specifically listed in Section 6.2.1 b. A nonbiologic investigational therapy c. An approved nonbiologic therapy in an investigational protocol d. Adalimumab 7. Within 60 days before enrollment, have received any of the following: a. Infliximab b. Certolizumab pegol c. Any other investigational or approved biological agent, other than local administration for non-IBD conditions (eg, intra-ocular injections) 8. Any prior exposure to natalizumab, efalizumab, or rituximab 9. Use of topical (rectal) treatment with 5-ASA or corticosteroid enemas/suppositories within 2 weeks before enrollment 10. Evidence of or treatment for C. difficile infection or other intestinal pathogen within 28 days before enrollment 11. Currently require or are anticipated to require major surgical intervention for CD (eg, bowel resection) during the study. (Minor surgical procedures to treat complications of CD [eg, fistulotomy] are acceptable.) 12. History or evidence of adenomatous colonic polyps that have not been removed 13. History or evidence of colonic mucosal dysplasia (vd protocollo v 1 16/09/2010)


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
moderate to Severe Crhon`s Disease
MedDRA version: 13.1 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 10017947 - Gastrointestinal disorders
Intervention(s)

Product Name: Vedolizumab
Product Code: MLN0002
Pharmaceutical Form: Powder for infusion
INN or Proposed INN: Monoclonal antibodies
CAS Number: 943609-66-3
Current Sponsor code: MLN0002
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 300-
Pharmaceutical form of the placebo: Powder for infusion
Route of administration of the placebo: Intravenous use

Primary Outcome(s)
Main Objective: To determine the effect of vedolizumab induction treatment on clinical remission at Week 6 in the subgroup of patients defined as having failed tumor necrosis factor alpha (TNFa) antagonist therapy (TNFa subpopulation)
Primary end point(s): Proportion of patients in clinical remission at Week 6 in the TNF alpha subpopulation
Secondary Objective: To determine the effect of vedolizumab induction treatment on clinical remission at Week 6 in the entire study population To determine the effect of vedolizumab induction treatment on clinical remission at Week 10 in the TNF? subpopulation and in the entire study population To determine the effect of vedolizumab induction treatment on sustained clinical remission (ie, clinical remission at both Week 6 and Week 10) in the TNFa subpopulation and in the entire study population To determine the effect of vedolizumab induction treatment on enhanced clinical response at Week 6 in the TNF asubpopulation
Secondary Outcome(s)
Secondary ID(s)
2009-016488-12-NL
C13011
Source(s) of Monetary Support
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history